The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
· Group revenue increased by 17% to £60.2 million (H1 2018: £51.3 million) continuing the strong growth trajectory from previous periods.
· Revenue from Ongoing Operations increased by 28% to £51.4 million (H1 2018: £40.0 million), which includes a 45% increase in Indian revenue to £40.9 million (H1 2018: £28.3 million).
· Adjusted EBITDA increased by 25% to £3.6 million (H1 2018: £2.9 million).
· EBITDA increased by 30% to £2.3 million (H1 2018: £1.8 million).
· Overall, currency movements across our international markets adversely impacted reported results. At constant currency:
· Group revenue increased 19%.
· Revenue from Ongoing Operations increased 30%.
· Adjusted EBITDA increased by 34%.
· EBITDA increased by 44%.
· Profit before tax reduced by 36% to £0.9 million (H1 2018: £1.3 million).
· Customer numbers have increased to 9.0 million (H1 2018: 6.7 million; 31 December 2018: 8.2 million).
05-Aug-19 16:33:51 4.50 100,000 Sell* 4.20 5.45 4,500 O
01-Aug-19 16:04:45 4.50 100,000 Sell* 4.22 5.00 4,500 O
31-Jul-19 16:34:26 4.50 100,000 Sell* 4.20 5.45 4,500 O
30-Jul-19 16:23:10 4.50 100,000 Sell* 4.22 5.00 4,500 O
CPP Group are continuing to expand into new markets internationally. This includes the recent creation of an operational hub in Singapore which is our base to service adjacent markets in Southeast Asia and build on our existing presence in Malaysia. Since establishing ourselves in this region we are looking to grow our team.
6 months? I thought it was 3 months? Next year before exciting news is a long way off.
With a director trade occurring there will be decent news but not for six months from that deal as it would break all sorts of rules on insider trading. So it will be a bit quiet for a while unless people speculate on the news.
No trades for a few days! That doesn’t happen very often! Had there not been a director buying shares recently, I think my 6 years of being in here would be coming to an end. Any thoughts from anyone on the silence or should I just sit tight for a few more months?
Straight purchase or options vesting I wonder.
Share price is on the floor.
But has risen over last 2 days - why ?
CPP has been advised that Jason Walsh, Chief Executive Officer has purchased a total of 300,000 ordinary shares of 1 pence each in the Group (the "Ordinary Shares"). Following the purchase, Jason Walsh has a total beneficial interest in 732,854 Ordinary Shares, representing approximately 0.08% of the issued share capital of the Group. Paid 4.77 a share
Seems to have started?
Special resolutions passed:
To authorise the Company to purchase its own shares*
To disapply pre-emption rights*
https://www.legislation.gov.uk/ukpga/2006/46/part/17/chapter/3/crossheading/disapplication-of-preemption-rights
What a load of Boll---s ...... come on CPP... u don't need this ---just make money -- your have done before and can do again ----- just do it...........................:D
CPP are exhibiting at Mello2019 which may be worth attending hTTps://melloevents.com/event/
ShareSoc have a special discount for our full members to the Mello2019 show! So, if you are planning on going to the Mello event it may be worth joining us as a full member too here: hTTps://www.sharesoc.org/membership/full-membership/
You can save up to £60 on the £149 ticket if you join ShareSoc!
This is the headline: Insurer enjoys an Indian summer after storms in the UK
It goes down then shoots up — That’s CPP & AIM
certainly looks like pi`s are being shafted here,typical aim casino..
AIM market has lost almost all its benefits!
Its going down steadily regardless of positive or negative RNS. It's just a AIM market and directors knew what is going to happen when they switched to AIM market from FTSE. But they buying cheap shares for 1 pence and completely devaluing CPP share price. Unfortunately they are doing everything legally and eventually will destroy market price completely. There are many similar examples on AIM market with same outcome...
What is a 1 code trade?
For those who believe in it !! The 1 code trade occurred !!
Even better if it is. I just find it odd that the directors would buy more shares surely knowing that the yearly results were not going to be particularly profitable.I think a few good new contracts must about to land in the not too distant future. Lets hope so anyway.
Unless it’s actually a buy ...
1/4 million shares showing as sold @ 6p. If they have really been offered 6p for that many shares then I believe even more that something positive must be just around the corner..As always just a gut feeling and not to be acted upon. Good luck all
Yes ... forgot to mention the broker report .. was hoping others didn’t see it .. significant upside !!
The removal of significant regulatory restrictions has
created an important inflection point for CPP. In addition to
enabling it to extract greater value from its back book of
insurance policies, it has helped reposition the group to
drive organic growth in its core markets. This combined
with the delivery of significant cost savings, should see
profits more than double over the next two years. Whilst we
appreciate certain execution risks remain, the success to
date of the new management team leaves us to believe
these are being overly discounted. We initiate with a BUY
and 15p target price.
India drives top line growth
Ongoing revenues are set to grow at
15% pa, reflecting the strength in its
end markets and partnerships. India,
the group’s growth engine, is
expected to grow at 17% pa.
Don’t ignore the back book
Whilst in decline, the group's
restricted operations are extremely
profitable. We estimate this back
book has an NPV of £36.7m, with
optionality to improve this.
Margins should also double
Execution of the recently-announced
restructuring, alongside leveraging its
recent Globiva acquisition should
drive a doubling in group EBIT
margins by FY20.
73% upside to DCF based TP
The shares trade at a 20% discount
to our SoTP valuation of 10.4p.
Multiple analysis suggests the shares
could more than double, and we see
73% upside to our TP of 15p.
Ignore the revenue figures. It is all about the profit. Saying that, profit was stunted due to the investments made which are anticipated to save approx. £4m in the coming year. So well worth taking the hit now considering they have the cash to do it.